318 related articles for article (PubMed ID: 25956715)
1. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
Mahmić-Kaknjo M; Marušić A
Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
[TBL] [Abstract][Full Text] [Related]
2. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
[TBL] [Abstract][Full Text] [Related]
3. Essential Medicines in a High Income Country: Essential to Whom?
Duong M; Moles RJ; Chaar B; Chen TF;
PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544
[TBL] [Abstract][Full Text] [Related]
4. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
5. The interpretation of China national essential medicines list 2018.
Zuo W; Mei D; Sun W; Tang X; Niu Z; Gao D; Zhang B
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):191-200. PubMed ID: 31914825
[No Abstract] [Full Text] [Related]
6. Essential medicines availability is still suboptimal in many countries: a scoping review.
Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
[TBL] [Abstract][Full Text] [Related]
7. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL-EASTERN AND SOUTH EUROPE COUNTRIES: BOSNIA AND HERZEGOVINA.
Guzvic V; Catic T; Kostic M
Int J Technol Assess Health Care; 2017 Jan; 33(3):390-395. PubMed ID: 28434417
[TBL] [Abstract][Full Text] [Related]
8. Use of evidence and negotiation in the review of national standard treatment guidelines and essential medicines list: experience from Ghana.
Koduah A; Asare BA; Gavor E; Gyansa-Lutterodt M; Andrews Annan E; Ofei FW
Health Policy Plan; 2019 Nov; 34(Supplement_2):ii104-ii120. PubMed ID: 31723963
[TBL] [Abstract][Full Text] [Related]
9. Essential medicines for emergency care in Africa.
Broccoli MC; Pigoga JL; Nyirenda M; Wallis L; Calvello Hynes EJ
Emerg Med J; 2018 Jul; 35(7):412-419. PubMed ID: 29627770
[TBL] [Abstract][Full Text] [Related]
10. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
11. Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?
Osorio-de-Castro CGS; Azeredo TB; Pepe VLE; Lopes LC; Yamauti S; Godman B; Gustafsson LL
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):402-412. PubMed ID: 29117642
[TBL] [Abstract][Full Text] [Related]
12. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
13. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
14. Essential medicines lists for children of WHO, India, South Africa, and EML of China: A comparative study.
Liu D; Cheng J; Zhang LL; Li YP; Zeng LN; Zhang C; Gui G
J Evid Based Med; 2017 Nov; 10(4):271-280. PubMed ID: 28276634
[TBL] [Abstract][Full Text] [Related]
15. [The essentiality and rationality of the Brazilian national listing of essential medicines].
Yamauti SM; Bonfim JR; Barberato-Filho S; Lopes LC
Cien Saude Colet; 2017 Mar; 22(3):975-986. PubMed ID: 28301004
[TBL] [Abstract][Full Text] [Related]
16. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM
Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of essential medicines lists: the South African case study.
Perumal-Pillay VA; Suleman F
BMC Health Serv Res; 2016 Dec; 16(1):687. PubMed ID: 27955710
[TBL] [Abstract][Full Text] [Related]
18. Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures.
Magarinos-Torres R; Lynd LD; Luz TCB; Marques PEPC; Osorio-de-Castro CGS
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):181-188. PubMed ID: 28371342
[TBL] [Abstract][Full Text] [Related]
19. Cochrane and its prospects in Bosnia and Herzegovina: Relying on Cochrane Croatia.
Mahmić-Kaknjo M; Puljak L; Markotić F; Fidahić M; Muhamedagić L; Zakarija-Grković I
Acta Med Acad; 2015; 44(1):58-67. PubMed ID: 26062698
[TBL] [Abstract][Full Text] [Related]
20. Social networks and health policy: the case of misoprostol and the WHO model essential medicine list.
Millard C; Brhlikova P; Pollock A
Soc Sci Med; 2015 May; 132():190-6. PubMed ID: 25818380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
